# FDA recall D-0562-2024

> **Breckenridge Pharmaceutical, Inc** · Class II · drug recall initiated 2024-05-17.

## Product

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle,  Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

## Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

## Distribution

Nationwide in the USA

## Key facts

- **Recall number:** D-0562-2024
- **Recalling firm:** Breckenridge Pharmaceutical, Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2024-05-17
- **Report date:** 2024-06-26
- **Termination date:** 2026-04-07

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Berlin, CT, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0562-2024

## Citation

> AI Analytics. FDA recall D-0562-2024. Retrieved 2026-07-17 from https://api.ai-analytics.org/recall/D-0562-2024. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*